Given the decrease in E2F targets, we further interrogated the expression of “activating” E2Fs within our RNA-seq analyses, demonstrating that E2F1 to E2F3 RNA expression was significantly decreased in response to NXP800 treatment across all prostate cancer cells studied (Fig. 3F; refs. 62, 63). The gene discussed is E2F3; the disease is prostate carcinoma.